MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 202 filers reported holding MYRIAD GENETICS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $208,520 | -32.1% | 13,000 | -1.9% | 0.01% | -25.0% |
| Q2 2023 | $307,135 | -0.2% | 13,250 | 0.0% | 0.01% | -7.7% |
| Q1 2023 | $307,798 | +77.9% | 13,250 | +10.9% | 0.01% | +30.0% |
| Q4 2022 | $173,000 | -12.6% | 11,950 | +14.9% | 0.01% | -9.1% |
| Q3 2022 | $198,000 | +4.8% | 10,400 | 0.0% | 0.01% | +10.0% |
| Q2 2022 | $189,000 | -27.9% | 10,400 | 0.0% | 0.01% | -16.7% |
| Q1 2022 | $262,000 | – | 10,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |